JPA Health, a leading integrated health agency globally, has strategically enhanced its service offerings by acquiring BioCentric, Inc., a distinguished medical communications agency known for its robust engagement with major pharmaceutical companies. This acquisition is poised to bolster JPA Health’s capabilities in medical communications and learning experiences, merging BioCentric’s expertise in scientific platforms, clinical trial acceleration, and healthcare professional (HCP) engagement with JPA’s comprehensive marketing and advocacy solutions.

BioCentric, founded in 2001 by Sherine Aly, has become a cornerstone in the medical communications sector, especially noted for its innovative use of serious games and gamification to drive meaningful engagement and positive behavioral changes in health communications. The company, headquartered in Collingswood, N.J., with additional operations in Lausanne, Switzerland, will continue under the leadership of Sherine Aly, who will serve as the Executive Vice President of Medical Communications at JPA Health.

Uniting Expertise for Enhanced Healthcare Solutions

Carrie Jones, CEO of JPA Health, expressed enthusiasm about the integration, highlighting the complementary strengths of both organizations. “This acquisition is a great union, bringing together BioCentric’s medical prowess with JPA’s deeply rooted expertise across marketing, patient advocacy, and corporate communications. Our clients will benefit from a fully integrated agency that can deliver unparalleled solutions to help them achieve their goals efficiently and effectively,” said Jones.

Sherine Aly echoed this sentiment, emphasizing the potential for elevated service offerings through the merger. “Joining JPA Health allows us to elevate our work to new heights. Our shared commitment to improving lives by connecting healthcare stakeholders and leveraging the latest technological innovations will unlock powerful and creative synergies,” Aly noted. “Together, we can now offer our clients end-to-end solutions that make a real difference in patients’ lives.”

Strategic Growth and Technological Integration

This acquisition marks another significant step in JPA Health’s expansion strategy, following its September 2023 acquisition of True North Solutions, a firm specializing in predictive analytics, artificial intelligence, and natural language processing. The integration of True North Solutions and BioCentric underscores JPA Health’s commitment to providing comprehensive, data-driven, and high-impact services to clients across diverse sectors including life sciences, public health, and government.

With over 120 employees spread across its U.S. and European offices, JPA Health is set to offer a more integrated and synergistic suite of services. This includes corporate communications, brand marketing, patient engagement, and scientific storytelling, all underpinned by shared values and a vision dedicated to advancing medical science and improving health outcomes.

The merging of these entities not only enhances JPA Health’s ability to offer cutting-edge solutions but also solidifies its position as a leader in the health communications field, equipped to meet the evolving demands of the healthcare sector.

  BioCentric, BioCentric acquisition, health agency, JPA Health, medical communications, pharmaceutical engagement